Welcome back. Take a look at shares of Teva Pharmaceuticals surging this morning after delivering a beat across the board in Q3, pointing to strength in their branded drug portfolio, which contains treatments for schizophrenia, for migraines, and more. Joining us here first on CNBC is Tea CEO Richard Francis.Big move up for for the stock. Uh you lowered the high end of the revenue guidance, raised the low end of the earnings guidance. What what what's driving the strength.>> Hi Sarah, firstly, thank you for ...